Business
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing, with lead programs in hematology and genetic diseases.
Beam revenue more than doubled and the net loss narrowed, but free cash flow stayed deeply negative.
The read at a glance✓ Audited against SEC data
- Business mix — Base-editing genetic medicinesNote
- Revenue — Revenue rose 120.0%OK
- Losses — Net loss narrowed 78.8%OK
- Cash — Free cash flow fell to -$360.0MWatch
- Equity — Equity rose 68.8%OK
- Insiders — 0 purchases / 22 salesWatch
- Accounting — Altman-Z distress; other forensic fields unavailableWatch
Leadership changes
From Beam Therapeutics Inc.'s own filings, the day they're filed.
- Carole Ho · Directors · departureeff. 2026-02-27
- Sravan K. Emany · Chief Financial Officer · appointmenteff. 2024-12-05
- John Evans · Chief Executive Officer · departure
Latest filings
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-06-08
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Beam Therapeutics Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.